Search

Displaying results 4821 - 4830 of 10000 in total
  1. Drug

    Etofenamate

    go.drugbank.com/drugs/DB08984
    Investigational

    Etofenamate is used to treat muscle and joint paint. It is a non-steroidal anti-inflammatory drug (NSAID).

    Mixtures: THERMO RHEUMON 100 MG/G + 10 MG/G KREM, 50 G, THERMOFLEX %10 + %1 KREM, 50 GCategories: Non COX-2 selective NSAIDS
  2. Drug

    Etidocaine

    go.drugbank.com/drugs/DB08987
    Approved

    Etidocaine is marketed under the name Duranest. It is an injectable local anesthetic during surgery, labor, and delivery. … Etidocaine has a long duration of activity, but has the main disadvantage of increased bleeding during oral surgery.

  3. Drug

    Eprazinone

    go.drugbank.com/drugs/DB08990
    ApprovedWithdrawn

    Eprazinone (trade name Eftapan) is a mucolytic drug, and relieves bronchospasms.

  4. Drug

    Chlorphenoxamine

    go.drugbank.com/drugs/DB09007
    ApprovedWithdrawn

    Chlorphenoxamine is marketed under the name Phenoxene. It is an antihistamine and anticholinergic used to treat itching as well as for its antiparkinsonian effect.

    Mixtures: SISTRAL C DRAJE , 20 ADETSynonyms: ETHENAMINE, 2-(1-(4-CHLOROPHENYL)-1-PHENYLETHOXY)-N,N-DIMETHYL-, 2-((P-CHLORO-.ALPHA.-METHYL-.ALPHA.-PHENYLBENZYL)OXY)-N,N-DIMETHYLETHYLAMINE
  5. Drug

    Benzoctamine

    go.drugbank.com/drugs/DB09021
    Experimental

    Benzoctamine is a drug with two main uses. It can be used as a sedative which does not depress the respiratory system, but rather stimulates it. … It can also be used as an anxiolytic with the same efficacy as chlordiazepoxide for treating anxiety neurosis.

    Synonyms: N-Methyl-9,10-ethanoanthracene-9(10H)-methanamine
  6. Drug

    Ledipasvir

    go.drugbank.com/drugs/DB09027
    Approved

    Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … therapy option in combination with [sofosbuvir] for the treatment of HCV genotypes 1a, 1b, 4, 5, and 6 [L852].

    Mixtures: HARVONI®Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  7. Drug

    Vorapaxar

    go.drugbank.com/drugs/DB09030
    Approved

    Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history … By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-Fluorophényl)-2-pyridinyl]vinyl}-1-méthyl-3-oxododécahydronaphto[2,3-c]furan-6-yl]carbamate d'éthyle, Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester
  8. Drug

    Miltefosine

    go.drugbank.com/drugs/DB09031
    ApprovedInvestigational

    Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. … The CDC has also recommended it as a first line treatment for free-living amebae (FLA) infections such as primary amebic meningoencephalitis and granulomatous amebic encephalitis.

    Categories: P-glycoprotein substratesSynonyms: hexadecyl 2-(trimethylazaniumyl)ethyl phosphate
  9. Drug

    Albiglutide

    go.drugbank.com/drugs/DB09043
    ApprovedInvestigationalWithdrawn

    Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). … It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.

    Categories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 Agonists
  10. Drug

    Naloxegol

    go.drugbank.com/drugs/DB09049
    ApprovedInvestigational

    Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. … It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InhibitorsSynonyms: (5α,6α)-17-Allyl-6-[(20-hydroxy-3,6,9,12,15,18-hexaoxaicos-1-yl)oxy]-4,5-epoxymorphinan-3,14-diol